New UK drugs price scheme: two years of flat growth, no pricing role for NICE
This article was originally published in SRA
Executive Summary
The Department of Health in England has published details of the new Pharmaceutical Price Regulation Scheme agreed with the drug industry body, the ABPI, under which the industry has agreed to keep National Health Service drug spending flat for the first two years of the scheme1,2.